Related Experiment Video
Updated: May 30, 2026
06:27
A 3D Spheroid Model as a More Physiological System for Cancer-Associated Fibroblasts Differentiation and Invasion In Vitro Studies
Published on: August 8, 2019
Integrin α3β1 as a breast cancer target
Sita Subbaram1, C Michael Dipersio
1Albany Medical College, Center for Cell Biology & Cancer Research, Albany, NY 12208, USA.
Expert Opinion on Therapeutic Targets
|August 16, 2011
Summary
The integrin alpha-3 beta-1 (α3β1) shows promise as a breast cancer target. Further research is needed to understand its mechanisms and identify optimal therapeutic strategies for targeting this integrin.
Area of Science:
- Integrin biology
- Cancer research
- Drug development
Background:
- Integrins mediate cell adhesion and signaling, crucial for cancer progression and metastasis.
- The laminin-binding integrin α3β1 is increasingly recognized as a potential anti-cancer target in breast cancer.
Purpose of the Study:
- To review recent studies on integrins as anti-cancer targets.
- To highlight the potential of integrin α3β1 as a therapeutic target for breast cancer.
- To identify knowledge gaps for exploiting α3β1 therapeutically.
Main Methods:
- Review of preclinical studies and literature from the past decade.
- Analysis of integrin functions in cancer progression and metastasis.
- Identification of therapeutic strategies targeting integrins.
Main Results:
- Integrins play critical roles in tumor cell proliferation, survival, migration, and angiogenesis.
- Integrin α3β1 has emerged as a promising target due to its involvement in tumor cell behaviors.
- Several studies support the development of integrin antagonists as anti-cancer therapeutics.
Conclusions:
- While α3β1's tumor-promoting functions suggest it's a viable target, understanding its precise molecular mechanisms in breast cancer is essential.
- Identifying specific α3β1 functions to antagonize is crucial for successful therapeutic exploitation.
- Further research is needed to bridge knowledge gaps for effective α3β1-targeted therapies.
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:10Integrins
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...